Abstract |
Background The prognosis of patients with metastatic carcinoma of the biliary tract (mBTC) is poor and a systemic therapy with gemcitabine and platinum-based is the gold standard. The addition of bevacizumab to the chemotherapy might increase patients' survival. Our aim was to assess and compare the efficacy of GEMOX ( gemcitabine and oxaliplatin regimen) plus bevacizumab to GEMOX alone in mBTC. Methods Patients with mBTC who received the GEMOX- bevacizumab (n = 32; Group A) or GEMOX (n = 25; Group B) regimen as first-line treatment were compared. Treatment was repeated every two weeks until disease progression or unacceptable adverse effects occurred. The primary evaluation criterion was the progression-free survival (PFS). Results A quarter of patients (8/32) from Group A and a fifth of patients (13/25) from Group B had an objective response. The median PFS was 6.48 months and 3.72 months in Group A and B, respectively (p = 0.049). The median OS was 11.31 months and 10.34 months in Group A and B, respectively. Grade 3/4 sepsis was identified in 9.4% and 12% in Group A and B, respectively, (p = 0.64). Conclusion In mBTC, the addition of bevacizumab to GEMOX increased the progression-free survival and was associated with manageable toxicity. These data pave the way for further evaluation of antiangiogenic agents in mBTC.
|
Authors | Marie Bréchon, Marie Dior, Johann Dréanic, Bertrand Brieau, Marie-Anne Guillaumot, Catherine Brezault, Olivier Mir, François Goldwasser, Romain Coriat |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 36
Issue 1
Pg. 156-162
(02 2018)
ISSN: 1573-0646 [Electronic] United States |
PMID | 28762171
(Publication Type: Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Organoplatinum Compounds
- Deoxycytidine
- Bevacizumab
|
Topics |
- Aged
- Angiogenesis Inhibitors
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bevacizumab
(therapeutic use)
- Biliary Tract Neoplasms
(drug therapy)
- Deoxycytidine
(analogs & derivatives, therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Organoplatinum Compounds
(therapeutic use)
- Progression-Free Survival
|